New Diagnostic Imaging Agent Identifies Clear Cell Renal Cancer

Radiolabeled 89Zr-DFO-girentuximab PET/CT can accurately and noninvasively identify clear cell renal carcinoma, with minimal toxicity, say researchers reporting results from the phase 3 ZIRCON trial.

Related Keywords

United States ,California ,Pennsylvania ,Fox Chase Cancer Center ,Fox Chase ,Philadelphia ,American ,Robert Uzzo ,Los Angeles ,Brianm Shuch ,University Of California ,Telix Pharmaceuticals ,American Society Of Clinical Oncology ,Kidney Cancer Program ,Clinical Oncology ,Genitourinary Cancers ,Medscape Medical News ,Malignant Kidney Neoplasm ,Kidney Cancer ,Renal Cell Cancer ,Renal Cell Carcinoma ,Ancer Kidney ,Ancer Renal Cell ,Biopsy ,Adrenal Cancer ,Cancer ,Alignant Neoplasia ,Arcinoma ,Scan ,Biologic Therapy ,Prostate Carcinoma ,Alignant Prostate Neoplasm ,Prostate Cancer ,Ancer Prostate ,Computed Tomography ,It ,Tumor ,Histology ,Kidneys ,Antigens ,Monoclonal Antibody ,Etuximab ,Ituximab ,P ,